Sarepta Therapeutics Stock Analysis (NASDAQ:SRPT)

Add to My Stocks
$29.93 $0.25 (0.84%) SRPT stock closing price Mar 24, 2017 (Closing)
Watch Robo Advisor Video of SRPT Stock Analysis
Sarepta Therapeutics
Updated on : Mar 24, 2017
previous close
SRPT 29.9 (0%)
S&P 500 2344 (0%)
Closing Price On: Mar 24, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Biomed-Genetics
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2016-Q4
$million
%
YOY GROWTH
Compared to the industry
Long Term Growth
5 Year CAGR:
-35.1%
5 Quarter Net Profit
Net Margins
2016-Q4
%
LTM Margin
Debt/Equity Ratio
Debt:
16.2M
Debt/Equity Ratio:
 0.05
Compared to the industry
Cash Flow
Operating cash flow:
-$81.2M
Net Income:
-$88.5M
PROS      CONS
Low Debt Burden
Long Term Growth
Net Margins
ROE
FCF Margin
Rating: ★★★★★★★★★★ (0/5)
Other Metrics
Return on Equity:
-99.5%
Free Cash Flow Margin:
-388.2%
Double Tap To Exit Full Screen
0:00
/

Sarepta Therapeutics Analysis Video

141 5 2

View Sarepta Therapeutics stock analysis video. This is our SRPT analyst opinion covering the buy and sell arguments for SRPT stock.

Sarepta Therapeutics Inc Stock Rating (1.3/5)

Our Sarepta Therapeutics stock opinion is based on fundamentals of the company. This Sarepta Therapeutics stock analysis is based on latest Q4 earnings for 2016. The stock price analysis takes into account a company's valuation metrics.

Should you buy SRPT stock?

  • With its debt/equity ratio of  0.05, Sarepta Therapeutics has a lower debt burden when compared to the Medical average.

Should you sell SRPT stock?

  • The company saw an average annual sales decline of -35.1% in sales over the last 5 years.
  • Sarepta Therapeutics registered an average TTM Net loss of -4931%.
  • Sarepta Therapeutics has a negative ROE (Return On Equity) of -99.5%, indicating the company is not profitable.
  • The company has negative Free Cash Flows (FCF), with a negative FCF margin of -388.2%.

Comments on this video and Sarepta Therapeutics stock